| Antibody-drug conjugate (ADC) represents an innovative cancer treatment strategy. In recent years, with the advancement of biopharmaceutical technologies, ADC has demonstrated great potential in the treatment of gastrointestinal malignancies This article systematically reviews the current research status of ADC in the field of gastrointestinal malignancies, analyzes key targets and representative drugs in clinical development, and discusses optimization strategies and future directions, aiming to provide insights and references for the application of ADC in gastrointestinal malignancies. |
